Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response
Yan Mei(Guangdong Academy of Medical Sciences), Guangshuai Jia(Xuzhou Medical College), Xiuying Liu(Qingdao University), Yingzhao Wang(Sun Yat-sen University), Lingdan Chen(First Affiliated Hospital of Guangzhou Medical University), Xianwen Ren(Institute of Zoology), Dan Liu(Machine Intelligence Research Institute), Ji Zhang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xi Chen(University of Southern California), Xinyu Wang(Philadelphia College of Osteopathic Medicine), Hongyu Li(Zhejiang Shuren University), Zhigang Liang(State Key Laboratory of Respiratory Disease), Hui Yuan(Anhui Medical University), Qingling Zhang(Guangdong Academy of Medical Sciences), Qiu Li(Qingdao Agricultural University), Xiumei Wang(State Key Laboratory of New Ceramics and Fine Processing), Yong-Yi Feng(Sun Yat-sen University), Hongmin Bai(General Hospital of Guangzhou Military Command), Yiyi Li(University of Science and Technology Liaoning), Junjie He(Shanghai Maritime University), Jun Chen(Harbin Institute of Technology), Yi Wei(China University of Geosciences), Lixiang Wang(Sun Yat-sen University), Chunliu Huang(Sun Yat-sen University), Qibin Leng(State Key Laboratory of Respiratory Disease), Jing Liao(Guangzhou Medical University)
Cited by 219